JohnAHausdorffMD

Hematology • Monterey, CA

Physician

Join to view full profile

Dr. Hausdorff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hausdorff's full profile

Already have an account?

Office
5 Harris Ct
Bldg T, 2nd Flr Suite 201
Monterey, CA 93940
Phone+1 831-375-4105

Fax+1 831-372-5722
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1992 - 1995
SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1983 - 1987
State University of New York Downstate Medical Center College of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1991 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2013

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Getting by with a Little Help from Our Friends.
John Hausdorff, Grant Swanson> ;Journal of Palliative Medicine. 2021 Apr 1
7 citations
Palliative care pharmacist interventions in a community hospital.
Dharma Naidu, Kimberly Jones, David Kanyer, John Hausdorff> ;American Journal of Health-System Pharmacy. 2018 Jul 1